this elaborate architecture, there are four or five transcripts for PDE4A, four for PDE4B, possibly three for PDE4C, in addition to the five for PDE4D, for a total of al least 16 ORFs in humans. Undoubtedly, the presence of multiple promoters is necessary for appropriate tissueand developmental-specific expression, as well as for regulation by different extracellular stimuli (see below).
General Structural/Functional Properties of the PDE4 Proteins
From the characterization of PDE4 mRNAs and their corresponding protein products, it is established that 16 to 18 different PDE4 isoenzymes or variants are expressed in mammalian cells (2, 7) . These variants have closely related kinetic properties and ion requirements, and are all inhibited by rolipram. Structurally, they are composed of a highly conserved catalytic domain flanked by domains with regulatory functions. These domains at the carboxyl and amino terminal end of the PDE4 are often variant-specific (Fig. 2) . The structure of the PDE4B catalytic domain has been solved at the atomic level (8) , paving the way to the modeling of the catalytic domain of other PDE4s, or even members of other PDE families. This domain is composed of seventeen alpha helices connected by loops, with helices 6-13 containing residues critical for substrate binding and coordination of two metal ions involved in catalysis. [8] [9] [10] [11] [12] [13] [14] [15] [16] are clustered in subdomains allowing different conformational states of the catalytic center (8) .
Though the binding to Me1 (Me1 = metal ion binding site 1 probably occupied by Zn 2+ ) appears to be stable, the Mg 2+ or Mn 2+ binding to Me2 may be subject to rapid exchange, a finding that impacts several models of conformational changes in the catalytic domain (9) . Structural analysis and mutagenesis (10, 11) have identified several residues involved in substrate or inhibitor binding and for cAMP hydrolysis as well as for ion coordination.
Unfortunately, the spatial relationship between the catalytic domain and the surrounding domains is still unknown because the physico-chemical properties of full-length proteins have prevented the generation of useful crystals. Nevertheless, it is widely accepted that domains at the amino and carboxyl terminus of the PDE4 protein exert important constraints on the conformation, and therefore on the enzymatic function of the catalytic core. This concept is inferred by several findings. On the amino terminal side of the catalytic domain, two highly conserved regions, termed upstream conserved regions 1 and 2 (UCR1 and 2), have been identified in PDE4 (12) . Depending on the presence of UCR1 and UCR2, PDE4 variants can be 4 distinguished into two major subgroups, the long and short forms (Fig.2) . The long forms include UCR1 and UCR2, whereas the short forms contain only UCR2 or a portion of this domain. The UCR1/UCR2 cassette functions as a regulatory domain that controls the conformation of the catalytic domain. Long PDE4s are phosphorylated at a site present in the amino terminus of UCR1 and this posttranslational modification increases the V max of the enzyme up to fourfold (see below). In addition, nested deletions or controlled proteolysis of PDE4D, which cleaves UCR1 and UCR2 away from the catalytic domain, cause an activation of catalysis (10, 13) .
Together with the finding that an antibody that binds the carboxyl terminus of UCR2 induces an increase in V max (13) , these properties of the long forms have led to a model whereby UCR1
phosphorylation modulates the interactions of UCR2 with the catalytic domain, ultimately altering its conformation and activity. Using yeast two-hybrid assays, it has been determined that UCR1 and UCR2 interact with each other (13, 14) . This interaction, thought to be intramolecular, is most likely relevant to the mechanism of enzyme activation by phosphorylation (13, 14) .
However, we have recently provided evidence for a major role for the UCR1-UCR2 domain in the quaternary structure of PDE4. Splicing variants containing both modules behave as dimers, whereas variants with one of the two UCRs missing behave as monomers (15) . This dimerization is most likely critical for transmitting the conformational changes at the amino terminus to changes in conformation of the catalytic domain.
It is well established that a subgroup of PDE4 inhibitors, the prototype being rolipram, bind to the enzyme with kinetics that indicates the presence of multiple conformational states (16 , and in view of FRET data using fluorescent compounds, it has been proposed that the high affinity state is due to the occupancy of the Me2 binding site by Mg
2+
, whereas the low affinity binding site reflects inhibitor binding to an apoenzyme (17) . Although the hypothesis is quite appealing, additional data suggest that either more than two conformers are present, some of which are due to a loss of metal binding, or more likely, the UCR1/UCR2 domain is the primary determinant of multiple conformations of the catalytic domain. This latter hypothesis is consistent with the differences in rolipram affinity observed in PDE4 in the phosphorylated and dephosphorylated states (18) , in PDE4s in complex with other proteins (19) , and in PDE4s exposed to thiol reagents (20) .
The presence of multiple conformations of PDE4 is relevant for drug design because it has been proposed that the low affinity conformation is associated with the therapeutic effects of PDE4 inhibitors, whereas the high affinity conformation correlates with undesirable CNS and the gastric side effects of these compounds (16, 21) . Indeed, compounds that do not favor the high affinity state of the enzyme often have fewer CNS side effects (21).
PDE4 Regulation and Its Role in cAMP Signaling
In the seventies and eighties, the synthesis of second generation inhibitors provided important tools to distinguish PDE4-specific functions from those of other PDEs. In general, treatment with PDE4-selective inhibitors causes an increase in intracellular cAMP with enhancement or suppression of distal responses depending on the cell context. However, it is unclear whether functional changes that follow PDE4 inhibition are exclusively due to changes in cAMP "steady state" or whether additional, more subtle, and local disruptions of cAMP signaling produce the myriad effects reported in the literature. Because they participate in a number of feedback regulations involved in cell desensitization, adaptation, signaling cross talk, and cAMP signal compartmentalization, PDE4s are considered important cAMP homeostatic regulators.
Even though compounds with lower potency for PDE4C have been described (21), the PDE4 inhibitors thus far developed are nonselective because they inhibit PDE4A, PDE4B, and PDE4D isoforms with comparable IC 50 s. Thus, the question of distinct or overlapping functions of the PDE4s could not be addressed using a pharmacological approach. A genetic strategy of PDE4 gene inactivation has allowed the first insight into the function of different PDE4 proteins.
Because clearly distinguishable phenotypes have been observed in the PDE4B and PDE4D null mice, one can conclude that each PDE4 gene subserves distinct functions (22, 23) . To some extent, this specificity may reflect differences in the promoters of PDE4 genes, allowing expression of different proteins at different times during the life cycle of distinct cells. Because of the large array of splicing variants with distinct biochemical properties, it is more difficult to determine the extent of the overlap in the function of different PDE4 proteins. Certainly, differences in enzyme regulation or protein/protein interaction suggest specialized functions for each variant.
PDE4 Regulation by PKA-Mediated Phosphorylation
The phosphorylation and activation of a PDE4 was demonstrated in a TSH-responsive thyroid cell line (FRTL-5 cells) (24) . In these cells, TSH produces a rapid, PKA-mediated phosphorylation of PDE4D3 at Ser 54 and an increase in activity (25) . It is worth noting that the Ser and surrounding residues found in PDE4D3 are not only present in all mammalian PDE4 long splicing variants but are also conserved through evolution from C. elegans to human, thus implying a critical function for this domain in cell signaling. Phosphorylation of this site also causes a variable increase in activity in other long PDE4 variants in overexpression systems (26, 27) . Activation of native PDE4D3 and PDE4D5 by phosphorylation has been demonstrated in vascular smooth muscle and lymphocytic cell lines (18, 28, 29) .
Together with increased V max , phosphorylation causes an increase in affinity of PDE4D3
for Mg 2+ (25) . This finding has led to the proposal that an increased occupancy of Me2 of PDE4 causes changes in conformation and/or the increase in catalysis, as well as the observed changes in rolipram binding (18, 25) . Regardless of the exact mechanism, these data underscore the idea that modifications at the amino terminus of PDE4 are reflected in conformational changes in the catalytic pocket.
Presence of a PDE4D/PKA Complex in the Cell
PDE4D3 phosphorylation contributes to cAMP homeostasis and to the shape of the cAMP transient because inhibition of PDE4D3 phosphorylation causes an increase in the intensity of the cAMP transient induced by TSH, whereas activation of PDE4D3 by cAMP analogs decreases cAMP levels (30) . However, this feedback regulation must have additional functions that cannot be probed simply by measuring the overall intracellular cAMP concentration. This broader impact of PDE4 phosphorylation is implied by the observation that PDE4D3 and the PKA holoenzyme exist in a complex coordinated by the A kinase anchoring proteins (AKAPs) (31, 32) .
In rat Sertoli cells of the testis and cardiac myocytes, a PKA/PDE4D complex has been identified by co-immunoprecipitation and immunolocalization of PDE4D and RII. (31, 32) (Fig.3) . The presence of AKAP 450 and mAKAP in these complexes has been inferred by coimmunoprecipitation of these anchoring proteins in native or overexpressed complexes.
The functional consequences of the presence of these AKAP/PKA/PDE4D complexes can be inferred by the fact that PDE4D3 is phosphorylated and activated by PKA. Thus, a local feedback regulation serves to control cAMP access to an anchored PKA (31, 32 ). An increase in cAMP causes activation of the PKA that in turn promotes dissociation/activation of the C subunit. The activated C subunit phosphorylates accessible substrates that include the closely positioned PDE4D3. This phosphorylation causes PDE activation, a local decrease in cAMP, and a return of the PKA to a basal activity state.
Additional components of signaling are most likely present in the AKAP/PKA/PDE complex as AKAP450, and its splice variant Yotiao, also bind PP1 and PP2A (33) . Recently, it has been suggested that PDE4D3 is part of the complex that includes the Ca 2+ channel RyR, PKA, mAKAP, and PP1 in cardiomyocytes (34, 35) (Fig.3 ).
PDE4s and Regulation of cAMP Diffusion
Although cAMP is a small molecule that could potentially equilibrate throughout the cell in milliseconds (calculated diffusion rate 780 µm 2 s -1 ), the diffusion of this second messenger may be prevented in the cell either by physical barriers or rapid decay due to degradation by PDEs.
Twenty years of investigation have produced an array of data indicating the compartmentalization of cAMP function in cardiac myocytes (36) as well as other cells.
Although they all promote cAMP accumulation, β1 and β2 adrenergic agonists and PGE1 produce distinct patterns of protein phosphorylation in these cells and distinct changes in contractility (36, 37) . In addition, elegant work by Fishmeister and colleagues measuring L type channel activation by β adrenergic agonists has suggested that cAMP diffusion occurs only in a limited fashion and that PDEs, particularly PDE4s, may contribute to the prevention of this diffusion (38) .
By modifying a cyclic nucleotide-gated channel to bind cAMP in the micromolar range, Karpen and coworkers have developed a cAMP biosensor to study local cAMP concentration and diffusion (39) . Use of these modified channels expressed in heterologous systems to measure cAMP-regulated Ca 2+ currents have provided evidence that a pool of cAMP below the plasma membrane level does not equilibrate rapidly with the bulk of the cytoplasmic space. More importantly, they have been able to show that a PDE4 is important for regulating the cAMP concentration in this "microdomain" and have suggested that PDE4s are rapidly activated when a GPCR is occupied by its ligand (39) . Thus, a PDE4 regulation is likely involved in controlling cAMP access to its effectors close to the plasma membrane, the region most critical to signaling, again confirming a role for PDE4 targeting (Fig.3) .
A similar cAMP microdomain may be functioning in cardiac myocytes where it has been
shown that cAMP accumulation in response to β-adrenergic agonists occurs preferentially in a region overlapping with the Z band and the T tubules (40) . Even more significant, this preferential accumulation is obliterated by the inhibition of PDE4s. Myomegalin is a PDE4-interacting protein that may serve to anchor the long forms of PDE4 close to the Z band in the vicinity of the L-type channels, RyR and PKA, as indicated by immunolocalization data (34, (41) (42) (43) .
Other PDE4 Anchoring Proteins and Subcellular Targeting
An interaction of PDE4s with an array of different anchoring proteins, their inclusion in macromolecular signaling complexes, and localization in discrete compartments in the cell are probably the rule rather than the exception. The concept of PDE4s in macromolecular complexes and the subcellular localization has surfaced in several studies over the years; however, only recently has it come into focus with the development of more sensitive tools.
Among the different PDE4 variants, the short-form PDE4A1 is recovered mostly in the particulate fraction of brain homogenates. Studies from Houslay and collaborators have shown that this targeting is due to a unique amino terminus present in this variant. This domain has been characterized extensively and found to be the prototype of a domain (TAPAS-1) that binds lipids in the membrane bilayer (44) . PDE4A1 binds to phosphatidic acid via this domain, thus anchoring this protein in the Golgi region in proximity to phospholipase A. Phosphatidic acid binding has been reported for other PDE4s suggesting a localization close to the membrane structures (45) . Although phosphatidic acid binding increases the activity of PDE4 long forms, the exact physiological significance of the interaction with PDE4A1, in addition to targeting, remains to be elucidated.
A more dynamic localization of PDE4 to the plasma membrane in proximity to the GPCRs is derived from the discovery of an interaction between PDE4 and β-arrestin, a scaffold protein with the dual function of coordinating signaling molecules and receptor trafficking (46) .
In cells overexpressing the β-adrenergic receptor, β-arrestin and PDE4 are translocated to the membrane whereas this translocation is absent in MEF cells deficient in β-arrestin 1 and 2 (46) .
The presence of a GPCR/arrestin/PDE4 complex obviously has important implications in receptor signaling and desensitization. Thus, β arrestin recruitment to the phosphorylated receptor would bring a PDE to the complex, contributing to the termination of the signal and preventing the complex from further signaling through cAMP (46) .
Several PDE4 long isoforms contain a poly-proline motif that interacts with SH3 domains (7) . Such a domain has been mapped in human PDE4A4 and the orthologous rat PDE4A5 at the amino terminus as well as in the linker domain between the UCR2 and catalytic domain. This motif interacts with the SH3 domains of the Fyn/Lyn kinases in an overexpression/pull down assay. Although it is unclear to what extent these PDEs are in complex with the kinases in the intact cell, it is likely that other SH3 domain-containing proteins interact with PDE4s. It has been reported that these polyprolines are required for targeting to the particulate fraction in membrane ruffles and in a perinuclear region, a targeting that is only partially ablated by the removal of the two SH3 binding domains (7) . Finally, PDE4D5 has been shown to interact with RACK1 through its unique amino terminal domain (47).
Other PDE4 Regulation by Phosphorylation: MAPK Feedback
During studies aimed at optimizing the expression of PDE4s, it was observed that the recombinant PDE4B2 expressed in insect cells is phosphorylated by MAPK at a serine in a carboxyl terminal SPS motif (48) . The implications of this finding have come into focus when it was demonstrated that PDE4D3 overexpressed in mammalian cells is phosphorylated in a similar motif by MAPK leading to an inhibition of the catalytic activity (49) . It has been proposed that this regulation of PDE4D and other PDE4 long forms by MAPK constitutes feedback regulation.
Inhibition of the PDE4 activity induces an increase in cAMP, and it has been speculated that the local activation of PKA in turn suppresses the MAPK cascade via phosphorylation of RAF (50) .
Pharmacological manipulation of the aortic smooth muscle cells shows that PKA phosphorylation and activation of PDE4D5 overcomes or obliterates the initial inhibition due to MAPK phosphorylation (51) . Undoubtedly, further work is required to understand the physiological significance of the intricate positive and negative regulations relevant to signal cross-talk.
An increase in PDE4A activity has also been observed after activation of the PI3K signaling pathway (52) . Although PDE3 isoforms are in this pathway, it is also possible that PDE4A is somehow regulated by kinases downstream of PI3K such as the p70S6 kinase.
cAMP Gating and Long-Term Feedback Regulations Involving PDE4 Expression
In addition to short-term regulation of PDE4 due to posttranslational modifications, the expression of PDE4 is regulated at the transcriptional level. In both the PDE4B and PDE4D
genes, a cAMP-regulated intronic promoter has been identified by deletion mapping (53, 54) .
This promoter includes several potential cAMP regulatory elements (CREs) as well as other elements involved in transcriptional regulation. Hormonal stimulation in vitro or in vivo as well as pharmacological manipulation of intracellular cAMP causes large increases in PDE4D and PDE4B mRNA and the corresponding short form proteins (55, 56) . In addition, mRNA stability may contribute to the overall increase in PDE4D and PDE4B mRNA (56) . Other promoters present in the PDE4 genes also may be regulated by cAMP as an increase in PDE4D3 and PDE4D5 mRNA were recently reported after a sustained increase in cAMP (57, 58) .
In vitro studies have implicated this long-term induction of PDE4 in desensitization and
long-term cell adaptation as treatment with protein synthesis or PDE4 inhibitors to some extent reverses the desensitization state (2). In addition, mutations that chronically activate the cAMP signaling in vivo are associated with increased PDE4 expression (59) . A better understanding of the function of this feedback has come from the analysis of two phenotypes in the PDE4 null mice. In the ovary, the growth and maturation of the follicle is dependent on the concerted action of the pituitary gonadotropins FSH and LH (60) . FSH induces follicular granulosa cell replication and differentiation, whereas LH causes withdrawal from the cell cycle, terminal differentiation, and changes that promote ovulation of the mature oocyte. Both gonadotropins signal through cAMP and produce large increases in the mRNAs coding for the short forms of PDE4D. Ablation of the PDE4D gene causes a 75% decrease in the rate of ovulation and a consequent reduced fertility (22) . More importantly, the pattern of gene expression required for follicle maturation/ovulation is disrupted, demonstrating that the PDE4D feedback regulation is critical in cAMP signaling and cell differentiation.
Secondly, expression of the PDE4B2 short-form is induced by activation of the Toll receptor-related signaling pathway. In macrophages or monocytic cell lines as well as in circulating monocytes, LPS stimulation causes a large increase in PDE4B2 mRNA and PDE4B activity (23,61). In the PDE4B null mice, where this regulation is absent, LPS stimulation of TNF-α production is reduced by more than 90% (23). This finding indicates that the induction of PDE4B2 by LPS is a positive feedback regulation required to remove a negative cAMP constraint. Indeed, it is well established that cytokine production and activation of inflammatory cells is under negative regulation by cAMP, which functions as a gating pathway (62) .
Activation of these cells is associated with PDE4B2 induction to remove this negative constraint.
This finding is consistent with the pharmacological tenet that PDE4 inhibition blocks inflammatory responses and therefore is a promising therapeutic strategy for inflammatory disorders (21).
Additional Functions of PDE4 Inferred by the Phenotype of the PDE4D KO Mouse
The analysis of the phenotype of the PDE4D null mouse has provided additional insight into the by whole-body plethysmography or ex vivo by measuring tracheal ring contractility (64) (Mehats, paper submitted). The absence of a cholinergic-mediated contraction is likely due to an increased cAMP tone that follows ablation of the PDE4D in the airway. Indeed, cAMP levels are increased in the lungs of PDE4D KO mice. In addition, an increased sensitivity to agonists that activate adenylyl cyclase is present in this organ together with a decreased signaling through M2 cholinergic receptors that inhibits cyclase (64) . Therefore, PDE4D is critical for the control of cAMP levels in the airway and the fine tuning of the sensitivity to contracting and relaxing inputs. These findings also underline the potential of PDE4 inhibitors for the treatment of asthma.
In a different paradigm, anesthesia, monitored in mice as obliteration of the righting reflex, is induced by administration of α2-adrenergic agonists, and its duration is greatly reduced by the specific α2 antagonist MK-912 (65) . In mice deficient in PDE4D but not PDE4B, the duration of anesthesia is reduced by more than 50%. The α2-antagonists have an additional minor effect whereas PDE4 inhibitors that shorten the anesthesia in wild type mice have no effect in the PDE4D KO mice. These findings indicate that the decrease in cAMP induced by the α2 agonist is disrupted by removal of a PDE4, reemphasizing the critical role of PDE4D in the control of the balance between the positive and negative stimuli of the cAMP signaling pathway.
Furthermore, this observation is important from a pharmacological standpoint as it has been
proposed that the inhibition of anesthesia in mice is a correlate of emesis in ferrets (65), a major side effect produced by PDE4 inhibition. Golgi Golgi
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